transcend semaglutide Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Metabolic dysfunction-associated steatotic liver disease

Some side effects, like gallbladder problems, may appear later and require medical attention

1 **Includes fatigue and asthenia

PloS One 8, e73989

Blood glucose control may deteriorate as the medication's insulinotropic effects wane, particularly in patients with type 2 diabetes who rely on tirzepatide for glycemic management

These findings highlight the intricate interplay between mechanosensitive and heat-sensitive channels in the PNS and CNS, suggesting Piezo2 as a potential therapeutic target for visceral pain treatment

Collectively, these observations support the view that inter-individual variability in GLP-1 RA efficacy may, at least in part, reflect differences in baseline gut barrier integrity and microbiome functional capacity, which may distinguish responders from non-responders